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Cystic fibrosis is a lethal genetic disease caused by lack of functional cystic fibrosis trans-
membrane conductance regulator (CFTR) proteins at the apical surface of secretory epithe-
lia. CFTR is a multidomain protein, containing five domains, and its functional structure is
attained in a hierarchical folding process. Most CF-causing mutations in CFTR, including the
most common mutation, a deletion of phenylalanine at position 508 (∆F508), are unable
to properly fold into this functional native three dimensional structure. Currently, no high-
resolution structural information about full length CFTR exists. However, insight has been
gained through examining homologous ABC transporter structures, molecular modeling,
and high-resolution structures of individual, isolated CFTR domains. Taken together, these
studies indicate that the prevalent ∆F508 mutation disrupts two essential steps during
the development of the native structure: folding of the first nucleotide binding domain
(NBD1) and its later association with the fourth intracellular loop (ICL4) in the second trans-
membrane domain (TMD2). Therapeutics to rescue ∆F508 and other mutants in CFTR
can be targeted to correct defects that occur during the complex folding process. This
article reviews the structural relationships between CFTR and ABC transporters and cur-
rent knowledge about how CFTR attains its structure–with a focus on how this process is
altered by CF-causing mutations in a manner targetable by therapeutics.
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INTRODUCTION
Cystic fibrosis (CF) is an autosomal recessive disease affecting
more than 70,000 people world-wide. CF is caused by mutations in
the gene encoding the CF transmembrane conductance regulator
(CFTR) protein (Kerem et al., 1989; Riordan et al., 1989; Rom-
mens et al., 1989). CFTR functions as a regulated chloride channel
in the apical membrane of epithelia, where it plays a critical role
in maintaining the surface liquid layer. Lack of functional CFTR
results in thick secretions that cause gastrointestinal, reproduc-
tive, and respiratory system defects. Currently, CF patients most
commonly die of respiratory-associated problems.
More than 70% of CF patients have at least one allele with a
deletion of phenylalanine at position 508 (∆F508; Kerem et al.,
1989). Further sequencing of CF patient and non-patient CFTR
genes has been extensive, and hundreds of mutations have been
identified1. Many of these mutations have been validated as CF-
causing, while others are CF-associated but unstudied. The val-
idated CF-causing mutations are located throughout the CFTR
gene, and are inherited in almost all cases (Riordan et al., 1989;
Riordan, 2008). ∆F508 (Cheng et al., 1990; Thomas et al., 1992)
and many other CF mutations (Gregory et al., 1991) result in
mutant CFTR that does not properly fold and is retained in the
ER by cell protein quality control. The result is that more than
90% of mutant CFTR alleles produce a misfolded protein that is
recognized, mistrafficked, and degraded in the cell.
While we do not have high-resolution three dimensional struc-
tural information for full length CFTR, a great deal of correlative
1www.genet.sickkids.on.ca
information regarding this structure has been obtained via homol-
ogous structures, domain structures, molecular modeling, and
lower resolution techniques.
ABC TRANSPORTERS
Cystic fibrosis transmembrane conductance regulator is a mem-
ber of the ATP-binding cassette (ABC) transporter superfamily
of proteins, which includes membrane spanning proteins that
use nucleotide hydrolysis to transport substrates across the mem-
brane bilayer (Holland, 2003). While there is no full length high-
resolution structure for CFTR, there are structures for other ABC
transporters, providing insight into the structure arrangement and
functional mechanisms of CFTR. Most ABC transporters function
to move substrates either into the cytoplasm (importers) or out
of the cytoplasm (exporters). Exporters are found in both eukary-
otes and prokaryotes, while importers have only been found in
prokaryotes (Rees et al., 2009). The importance of prokaryotic
ABC transporters for cellular functions, such as import of nutri-
ents and export of toxins, is highlighted by their representation
as 5% of the Escherichia coli genome (Linton and Higgins, 1998).
In humans, 48 or 49 distinct ABC transporters have been identi-
fied, many of which are implicated in disease (Dean et al., 2001;
Gottesman and Ambudkar, 2001; Borst and Elferink, 2002). The
core ABC transporter architecture is comprised of two transmem-
brane spanning domains (TMDs) and two nucleotide binding
domains (NBDs). Many transporters also have accessory domains
with regulatory functions (Biemans-Oldehinkel et al., 2006). In
general, the TMDs are organized as two wings that open and close
in response to NBD movements resulting from ATP binding and
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hydrolysis (Figure 1; Moody et al., 2002; Smith et al., 2002; Locher,
2009; Rees et al., 2009). Additionally, at the external surface, many
prokaryotic importers interact with accessory proteins that play
a role in substrate transport (Biemans-Oldehinkel et al., 2006).
The domains are modular, and are found expressed individually,
in combinations, or as a single full length transporter to form the
functional protein (Locher, 2009).
ATP-binding cassette transporters have a conserved coupling
mechanism, whereby signals from the NBDs are transmitted to
the intracellular loops (ICLs) of TMDs to cause substrate trans-
port (Locher, 2009). The conserved NBDs form a sandwich around
two ATPs, with each site for ATP binding and hydrolysis requiring
both domains (Smith et al., 2002). Two subdomains are present in
each NBD. The catalytic subdomain contains the conserved Walker
A and B motifs, a Q-loop, and an H-motif, and the alpha-helical
subdomain contains the ABC signature motif, LSGGQ (Figure 1C;
Rees et al., 2009). Each active site is composed of components
from the catalytic subunit of one NBD and the alpha-helical com-
ponents of the other NBD in a head-to-tail arrangement (Smith
et al., 2002; Rees et al., 2009). The binding of ATP in these sites
drives the association of the NBDs (Moody et al., 2002).
The TMDs are proposed to function in an alternating access
model of transport and are the most variable among ABC trans-
porters (Chen et al., 2001; Dawson et al., 2007). ABC transporters
can be divided into three classes based on the TMD fold (Locher,
2009). Type I and II ABC importers contain different core trans-
membrane (TM) span topologies of 10 and 20 TM helices respec-
tively, with the latter tending to facilitate transport of larger sub-
strates (Locher et al., 2002; Hollenstein et al., 2007; Locher, 2009).
In both importer types, one TMD interacts with one NBD to form
two TMD-NBD units that together form a functional transporter
(Figure 1A; Locher, 2009). ABC exporters contain a core of 12 TM
helices, with each wing of the transporter made of both TMDs,
with each TMD interacting with both NBDs in a domain-swapped
fashion (Figure 1B; Dawson and Locher, 2006; Locher, 2009). In
this arrangement, the ICLs extend into the cytoplasm, positioning
the NBDs approximately 25 Å from the membrane (Figure 1B;
Locher, 2009). In exporters, the TMDs and NBDs are expressed
as TMD-NBD units, and eukaryotic exporters are most frequently
found as full length transporters (Nikles and Tampe, 2007).
CFTR AS AN ABC TRANSPORTER
Cystic fibrosis transmembrane conductance regulator is a mem-
ber of the ABC C subfamily, and is structurally homologous to
the domain-swapped exporters. Structures of homologous ABC
exporters such as bacterial Sav1866 (Dawson and Locher, 2006,
2007), bacterial MsbA (Ward et al., 2007), bacterial TM287/288
(Hohl et al., 2012), and mammalian P-glycoprotein (Aller et al.,
2009) have been solved. The available structural data in combi-
nation with sequence alignments form the basis for homology
models of full length CFTR that provide insight into its structure,
mechanisms of regulation, and signal transduction (Mendoza and
Thomas, 2007; Mornon et al., 2008, 2009; Serohijos et al., 2008).
The exporter structures are in both open and closed forms, giv-
ing insight into movements within the CFTR protein during a
transport cycle (Figure 2, open form; Ward et al., 2007; Locher,
2009; Mornon et al., 2009; Rees et al., 2009). The similarity of
CFTR movements to other ABC transporters is supported by
electron microscopy data in combination with a low resolution
crystal structure (Rosenberg et al., 2004, 2011; Zhang et al., 2009,
FIGURE 1 | ABC transporters contain a core architecture of twoTMDs
(blue and cyan) and two NBDs (light and dark gray). Signals from the
NBDs relating to ATP binding and hydrolysis result in wing-like TMD
movements that transport substrates across the membrane (gray rectangle).
In the outward facing configuration, the two NBDs bind ATP (red circles) and
are close together, with the TMDs open to the non-cytosolic side. In the
inward facing configuration, the NBDs are more distant without ATP bound,
and the TMDs are open to the cytosol. (A) In ABC importers, each TMD
interacts with a single NBD (Examples include BtuCD and MalFGK). (B) In
ABC exporters, the TMDs wrap around each other in a domain-swapped
fashion, with each TMD interacting with both NBDs (Examples include
Sav1866 and MsbA). (C) The two NBDs sandwich two ATPs in a head-to-tail
fashion. Each ATP binding and hydrolysis site is comprised of both NBDs,
containing the conserved structural motifs in the catalytic subdomain
including the Walker A and B, Q-loop, and H-motif (purple oval), and the ABC
signature motif in the alpha-helical subdomain (green oval).
Frontiers in Pharmacology | Pharmacology of Ion Channels and Channelopathies September 2012 | Volume 3 | Article 162 | 2
Patrick and Thomas Development of CFTR structure
FIGURE 2 | CFTR homology models are based on the ABC exporter
structures. The Sav1866 (pdb 2HYD) exporter is shown with domains
colored based on representative CFTR domains, with TMD1 (blue), NBD1
(light gray), TMD2 (cyan), and NBD2 (black). There is no homologous
structure for the CFTR R domain. The structure is in the outward facing
configuration, which for CFTR is the open channel. The view is shown in the
plane of the membrane (gray rectangle).
2011). The only high-resolution structures of CFTR domains are
of NBD1 (Lewis et al., 2004, 2005, 2010; Thibodeau et al., 2005)
and NBD2 (pdb 3GD7). As an ABC transporter, CFTR contains
two TMDs, two NBDs, and a unique regulatory R region trans-
lated from an mRNA transcript as a single polypeptide chain
(Riordan et al., 1989). Sav1866 based CFTR models have exten-
sive interdomain interactions between the TMDs and NBDs,
but lack regions without sequence homology, like the R domain
(Figure 2; Dawson and Locher, 2006; Mendoza and Thomas,
2007).
The NBDs of CFTR, like other ABC transporters (Moody
et al., 2002; Smith et al., 2002), interact in a head-to-tail fash-
ion forming two sandwiched ATP binding pockets made of both
domains (Vergani et al., 2005; Mense et al., 2006). Each NBD
has a catalytic subdomain that contains the Walker A and B
motifs and an alpha-helical subdomain that contains the con-
served ABC signature motif (Lewis et al., 2004; Thibodeau et al.,
2005). However, like several other members of the ABC C sub-
family, one ATP binding site is non-hydrolytic (Muallem and
Vergani, 2009). In this site, non-conservative mutations, which
are located in the NBD1 Walker B and switch motifs and in
the NBD2 signature sequence, result in tight binding and inef-
ficient ATP hydrolysis (Aleksandrov et al., 2002; Basso et al.,
2003; Gadsby et al., 2006). In general, CFTR ATP driven con-
formational changes include ATP binding, which results in an
NBD dimer that signals the TMDs to open. Then, hydroly-
sis of one ATP disrupts the NBD interface, the NBDs separate,
and the channel closes (Gadsby et al., 2006; Aleksandrov et al.,
2007; Muallem and Vergani, 2009). However, the driving forces
that control the gating transitions and the signals transmitted
by ATP binding and hydrolysis are a matter of debate (Gadsby
et al., 2006; Aleksandrov et al., 2007; Muallem and Vergani, 2009).
NBD1 also contains two non-conserved regions, a regulatory
insert (RI) near the N-terminus and a regulatory extension (RE)
near the C-terminus. Of these two regions, studies have focused
on the RI. The RI is disordered in the NBD1 crystal structures
and plays a role in regulation of CFTR channel gating, but is
not required for trafficking in the cell (Lewis et al., 2004; Thi-
bodeau et al., 2005; Aleksandrov et al., 2010). Furthermore, a
mechanism wherein RI movements alter ICL1-NBD1 interac-
tions to affect phosphorylation-dependent CFTR gating has been
proposed (Kanelis et al., 2010).
Like other domain-swapped exporters, the TMDs form two
wings containing TMs from both TMD1 and TMD2, such that
the first two TMs and last four TMs of each domain make a
wing (Figure 2; Dawson and Locher, 2006; Mendoza and Thomas,
2007). Based on the exporter structures, the wings move to open
and close the chloride channel for ion transport (Vergani et al.,
2005; Mornon et al., 2009). In each TMD, two alpha-helical
ICLs extend into the cytoplasm, with each having a distal cou-
pling helix that interacts with the NBDs (Mendoza and Thomas,
2007; Mornon et al., 2008; Serohijos et al., 2008). In combina-
tion, the four ICLs form four helix inner and outer bundles that
end in the coupling helices (Figure 2; Mornon et al., 2008, 2009).
Each coupling helix is parallel to the NBD surface, and forms a
largely hydrophobic interface (Mendoza and Thomas, 2007). In
CFTR, ICL2 interacts with NBD2, ICL4 interacts with NBD1, and
ICLs 1 and 3 interact with both NBD1 and NBD2. Importantly,
the F508 position in NBD1 is predicted to lie near the interface
between NBD1 and ICL4 (Mendoza and Thomas, 2007). Many
of the predicted interdomain interactions are also experimen-
tally validated by crosslinking studies (Chen et al., 2004; Mense
et al., 2006; He et al., 2008; Loo and Clarke, 2008; Serohijos et al.,
2008). Further complexity of the ICL-NBD interactions is gener-
ated by phosphorylation-dependent interactions between NBD1
and an ICL1 peptide (Kanelis et al., 2010). Additionally, crosslinks
between an ICL and the opposing NBD disrupt channel opening,
supporting the essential roles of these components for channel
function (He et al., 2008). Models predict specific residues are
critical for the interactions between the ICLs and NBDs, including
Y275 and W277 which form an interface with NBD2 (He et al.,
2008; Mornon et al., 2008); D173, S169, and R170 which are pre-
dicted to contact nucleotide and NBD1 (Mornon et al., 2008);
and S263 and E267 which stabilize ICL helical bundle structure
(Mornon et al., 2009). Notably, the W277 position is equiva-
lent to the R1070 position in ICL4 (Mornon et al., 2008) that
when mutated, R1070W, suppresses the ∆F508 mutation (Thi-
bodeau et al., 2010; Mendoza et al., 2012). These positions have
not yet been fully tested for their roles in the folding and function
of CFTR.
In summary, conformational signals generated in the NBDs in
relation to ATP binding and hydrolysis are transmitted by the ICLs
in the TMDs, resulting in chloride channel opening and closing
(Gadsby et al., 2006; Riordan, 2008). The interactions between
CFTR ICLs and NBDs have been validated by crosslinking stud-
ies (He et al., 2008; Serohijos et al., 2008) and complementation
of a mutant located in an NBD with a mutant in an ICL (Thi-
bodeau et al., 2010). The coupling helices of ABC transporters
are architecturally conserved without having a highly conserved
sequence (Locher, 2009), making prediction of essential positions
and residues difficult without a high-resolution full length CFTR
structure.
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Cystic fibrosis transmembrane conductance regulator is the
only known channel among the ABC transporters. In the alter-
nating access model, ABC transporters are open to one side of the
membrane bilayer at a time (Chen et al., 2001; Dawson et al., 2007).
In CFTR, channel formation abrogates this model, as one of the
gates that would normally block substrate transport must be atro-
phied or gone to allow chloride flux (Gadsby, 2009). With regard to
this, CFTR has been called a broken ABC transporter (Jordan et al.,
2008; Muallem and Vergani, 2009). Similar to other chloride chan-
nels, CFTR is not very selective among small monovalent anions
and has a relatively featureless pore (Gadsby et al., 2006; Gadsby,
2009). Putative residues that make the chloride channel have been
identified in TMs and in extracellular loops, with a focus on TM1
and TM6 (Linsdell, 2006). However, it is difficult to validate these
residues without better characterizing the TM span positions and
TMD structures. Further complicating the TMD structure is a
TMD1 N-terminal cytosolic region that regulates CFTR channel
activity through interactions with the R domain, neither of which
has a homologous structure (Naren et al., 1999; Chappe et al.,
2005).
The chloride channel activity of CFTR is regulated by the R
domain (Riordan, 2008). The R domain is largely unstructured
and has multiple sites that are phosphorylated by PKA, resulting
in CFTR channel activation (Gadsby et al., 2006; Baker et al., 2007).
Consistent with this, the unphosphorylated R domain has an
inhibitory effect on the CFTR channel (Rich et al., 1991; Csanady
et al., 2000). The R domain interacts with multiple other regions
of CFTR, including NBD1 and the N-terminus of TMD1 (Naren
et al., 1999; Baker et al., 2007; Kanelis et al., 2010). This evidence
suggests the R domain may act as a signal integrator to regulate
channel function via interactions with different regions of CFTR.
However, due to its lack of homology and disordered nature, the
R domain location within CFTR models remains unclear.
Many different modifications to the CFTR protein that may
impact its structure have been identified. For instance, CFTR
contains two N -linked glycosylation sites, NXS/T (X6=P), within
TMD2 that are core glycosylated in the ER lumen. This core
glycosylation is then modified in the Golgi to produce complex
glycosylated protein (Helenius and Aebi, 2001). The natural sites
within CFTR are regularly used to monitor its integration and cel-
lular trafficking by changes in electrophoretic mobility upon core
glycosylation, producing Band B at approximately 150 kDa, and
complex glycosylation, producing a diffuse Band C above 170 kDa.
The natural glycosylation sites are not required for cellular traf-
ficking from the ER and chloride channel function (Howard et al.,
1995; Chang et al., 2008; Glozman et al., 2009; Patrick et al., 2011).
However, recently, these sites have been found to influence the
efficiency of CFTR productive protein folding and early secretory
trafficking (Glozman et al., 2009), and cell surface retention and
turnover in post-ER cellular compartments (Chang et al., 2008;
Glozman et al., 2009). The impact of these and other modifica-
tions on the development of CFTR structure is an area of ongoing
study.
The combination of experimental and modeling studies pro-
vides significant insight into the CFTR structure, which allows
formation of models within which mechanochemical mechanisms
and the effect of CF-causing folding mutations can be framed.
However, since many CF-causing mutations, including ∆F508,
result in misfolding of the CFTR protein, the folded full length
structure may not adequately describe the relevant defects.
CFTR FOLDING AS A MULTIDOMAIN PROTEIN
Cystic fibrosis transmembrane conductance regulator, like other
ABC transporters, contains extensive interdomain surfaces (Rees
et al., 2009) that, in the case of CFTR, likely form during translation
(Zhang et al., 1998; Du et al., 2005; Kleizen et al., 2005; Thibodeau
et al., 2005). During protein translation, secondary structure can
begin to form early, even while the nascent chain is in the tunnel
of the ribosome (Kramer et al., 2001; Woolhead et al., 2004). For
CFTR, as translation continues each domain folds and can then
interact with previously translated domains to form multidomain
folding intermediates (Figure 3; Lukacs et al., 1994; Du et al., 2005;
Kleizen et al., 2005; Thibodeau et al., 2005; Cui et al., 2007; Che-
ung and Deber, 2008; Du and Lukacs, 2009). The current model
of CFTR folding holds that individual domain structures form
cotranslationally (Kleizen et al., 2005). Then, intermediate struc-
tures form and eventually a TMD1-NBD1-R-TMD2 structure is
produced that is required for cellular trafficking (Meacham et al.,
1999; Du et al., 2005; Cui et al., 2007; Du and Lukacs, 2009). Finally,
NBD2 posttranslationally incorporates into the CFTR structure
(Figure 3; Du et al., 2005). The addition of NBD2 confers a greater
folding efficiency and trafficking from the ER. Thus, although
NBD2 is not strictly required for CFTR trafficking (Pollet et al.,
2000; Cui et al., 2007; Du and Lukacs, 2009; Thibodeau et al.,
2010), its posttranslational association into the CFTR structure
(Du et al., 2005) may increase the yield of folded cellular CFTR.
Much of this model is based on individual CFTR domains form-
ing protease-resistant structures during translation (Zhang et al.,
1998; Kleizen et al., 2005). The order of interdomain interaction
formation and whether initial interactions are the same as those
in the final CFTR structure is not known.
Cystic fibrosis transmembrane conductance regulator fold-
ing occurs during translation as a linear polypeptide (Rior-
dan et al., 1989). However, many ABC transporter domains
are expressed separately, and later associate to form a func-
tional transporter (Locher, 2009). To some extent, CFTR retains
some ability to fold in this manner. CFTR can be expressed
as a split construct, which forms structure that traffics to the
cell surface and functions as a chloride channel (Ostedgaard
et al., 1997; Chan et al., 2000; Csanady et al., 2000; Du and
Lukacs, 2009). Additionally, expression of constructs contain-
ing TMD1-NBD1-R or R-TMD2-NBD2 formed chloride chan-
nels, likely as multimers (Sheppard et al., 1994; Devidas et al.,
1998). Finally, in the cell the minimal construct that traf-
fics from the ER contains TMD1-NBD1-R-TMD2, which forms
a chloride channel (Cui et al., 2007). These studies suggest
that the domains of CFTR, to a certain extent, can associate
posttranslationally to form a functional chloride channel. Yet,
CFTR is a linear chain, such that folding requires that each
domain attain structure in a more spatially confined manner.
The critical role of the primary sequence in the CFTR fold-
ing process is highlighted by the multitude of CF-associated
folding mutations identified throughout the protein (see text
footnote 1).
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FIGURE 3 | Hierarchical folding model of CFTR. Potential interdomain
interactions are indicated by red arrows, with several possible structural units
included during the translation process. In the cell, constructs lacking TMD2
do not traffic from the ER, whereas constructs containing TMD2 can traffic
from the ER. Reflecting this, a major structural rearrangement is depicted in
the presence of TMD2, as shown in the bottom panel. Eventually, NBD2 is
incorporated as the final step. There are many points during this process at
which the cell may monitor perturbations.
CFTR COTRANSLATIONAL FOLDING INVOLVES
INTERACTIONS WITH OTHER PROTEINS
Cystic fibrosis transmembrane conductance regulator folding
involves many proteins that act at different stages to aid folding
or recognize misfolding. This topic is extensively reviewed else-
where within this Research Topic. Briefly, the misfolded CFTR
is retained in the ER, and eventually degraded (Lukacs et al.,
1994) by the proteasome (Jensen et al., 1995; Ward et al., 1995).
Many proteins interact with CFTR in the ER lumen, ER mem-
brane, and cytoplasm, suggesting that the domains of CFTR are
differentially monitored during the biosynthetic process. Among
these identified interacting partners are the cytoplasmic proteins
Hsc/p 40, 70, 90, and associated co-chaperones CHIP (Strick-
land et al., 1997; Meacham et al., 1999, 2001; Younger et al.,
2006) and Aha1 (Wang et al., 2006), the ER membrane associ-
ated protein RMA1 (Younger et al., 2006; Grove et al., 2011),
the ER integral membrane proteins Derlin (Sun et al., 2006;
Younger et al., 2006; Wang et al., 2008) and BAP31 (Wang et al.,
2008), and the ER luminal-interacting protein calnexin (Pind
et al., 1994). After trafficking to the cell surface, CFTR inter-
actions with cytoskeletal proteins are important for its main-
tenance at this cellular location (Okiyoneda and Lukacs, 2007).
Also at the plasma membrane, peripheral protein quality control
is involved in the ubiquitination, internalization, and degrada-
tion of misfolded CFTR (Okiyoneda et al., 2010). Moreover, a
protein interactome for CFTR includes potential interactions far
beyond those that have been studied (Wang et al., 2006). How-
ever, it is not clear which proteins interact at the earliest stages
of folding/maturation and are responsible for initial and irre-
versible recognition of mutant CFTR. Furthermore, the structural
aspects of CFTR during folding that are important for forma-
tion of these interactions are unclear. These interactions paint
a picture of CFTR biogenesis whereby normal structural forma-
tion and interactions are formed with cellular folding and quality
control machinery, providing multiple points to monitor CFTR
folding.
CF-MUTANTS PERTURB CFTR COTRANSLATIONAL FOLDING
Cystic fibrosis-associated mutations have been found in every
domain of CFTR (see text footnote 1). Misfolded CFTR, specifi-
cally the ∆F508 mutant protein, is recognized by cellular quality
control machinery, accumulates in the ER (Cheng et al., 1990),
and is eventually degraded (Lukacs et al., 1994) by the proteasome
(Jensen et al., 1995; Ward et al., 1995). Many studies have identi-
fied CF-causing mutants that result in accumulation of CFTR in
the ER. Mutant effects have been categorized into classes based
on the resulting effect on CFTR (Welsh and Smith, 1993; Zielenski
and Tsui, 1995). The alterations include lack of protein production
(class I), defective protein maturation and early degradation (class
II), defective regulation of ATP interactions (class III), reduced
chloride transport (class IV), reduced transcripts though splicing
or promoter defects (class V), and increased cell surface turnover
(class VI; Welsh and Smith, 1993; Zielenski and Tsui, 1995). The
∆F508 mutation accounts for 70% of CF-causing mutant CFTR
alleles (Riordan et al., 1989), making class II defects the most
common cause of CF.
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Mutations within the CFTR protein, including ∆F508, may
perturb local protein structure and/or domain structure, or could
be surface exposed and perturb interactions with other domains
or proteins. For instance, in the NBD-ICL4 interface, mutants
in ICL4 including L1065P, R1066C, and A1067T alter traffick-
ing and chloride channel function (Cotten et al., 1996; Seibert
et al., 1996). Mutants in different domains alter biogenic interme-
diates of CFTR, suggesting that misfolding does not require full
length CFTR (Du and Lukacs, 2009). Furthermore, in full length
CFTR, the proteolytic stability of all domains was reduced for spa-
tially separate mutations, suggesting propagation of one mutant
to other domains (Rosser et al., 2008; Du and Lukacs, 2009). The
propagation of mutants could occur through a rearrangement step
involving multiple domains (Du and Lukacs, 2009), or through
coupled folding of the domains. As discussed, various components
of cell quality control recognize CFTR as it is created, such that
domain and multidomain states are likely differentially monitored
(Younger et al., 2006). For each mutation, the effect on individ-
ual domain folding and multidomain units plays a fundamental
role in determining the mechanisms by which that mutation is
recognized and managed within the cell.
An example of mutants similarly located within CFTR with
different local mechanisms of misfolding are the G85E and G91R
mutations. These mutations are located near or within the TM1
span within TMD1. Both mutations have been demonstrated to
disrupt later steps in CFTR folding, including interdomain interac-
tions, which have been proposed to result in mutant recognition by
ER quality control machinery (Xiong et al., 1997). Recently, G85E
was found to dramatically alter the conformation/integration pro-
file of TM1 (Patrick et al., 2011). Such an alteration would occur
at the earliest steps of translation and integration, and could be
recognized as a very early misfolding event by ER quality con-
trol machinery. The G91R mutant was predicted to have a similar
effect on CFTR (Xiong et al., 1997), but this proved not to be true
with regards to the TM1 conformation/integration profile (Patrick
et al., 2011). Interestingly, the corrector compound four rescues
G91R but not G85E-CFTR (Grove et al., 2009), suggesting the dif-
ferences in the mutant molecular pathologies may be relevant for
their ability to benefit from specific treatments to rescue defective
CFTR. The detailed mechanistic study of CF-causing mutations
provides a better fundamental understanding of membrane pro-
tein misfolding and mechanisms for approaching mutant specific
therapy for CF patients.
FOLDING OF NBD1 AND∆F508-NBD1
The best studied disease-causing mutation,∆F508, alters multiple
steps during CFTR folding. Particular focus has been given to fold-
ing of NBD1, wherein F508 resides. High-resolution crystal struc-
tures of both NBD1 and ∆F508-NBD1 have been solved (Lewis
et al., 2004, 2005; Thibodeau et al., 2005; Mendoza et al., 2012).
These structures place F508 on the domain surface, and ∆F508
does not cause significant perturbations in the crystal structure
(Lewis et al., 2005). However,∆F508-NBD1 has an increased ten-
dency to aggregate and is destabilized, indicating a disruption
during folding that is not represented in these native structures
(Qu and Thomas, 1996; Lewis et al., 2005; Thibodeau et al., 2005).
Consistent with this, a non-native conformation of NBD1 has
been identified that is promoted by∆F508 and linked to increased
aggregation (Hoelen et al., 2010; Richardson, unpublished data).
The NBD1 structure is obtained cotranslationally (Kleizen et al.,
2005; Hoelen et al., 2010; Khushoo et al., 2011). During transla-
tion,a ligand-dependent N-terminal compact structure forms,and
upon completion of NBD1 translation another compact structure
forms (Khushoo et al., 2011). The compact N-terminal structure
is not affected by ∆F508, suggesting that the folding error likely
occurs at a later step of NBD1 folding (Khushoo et al., 2011). The
∆F508 misfolding begins in NBD1, making this an attractive tar-
get for correcting∆F508-CFTR. The∆F508 mutant effects can be
partially rescued independently by suppressor mutations within
NBD1 (Teem et al., 1993; Qu et al., 1997; DeCarvalho et al., 2002;
Hoelen et al., 2010). Importantly, the∆F508 effects on NBD1 also
manifest during translation of the full length CFTR (Kleizen et al.,
2005).
In full length CFTR, ∆F508 effects multidomain stability and
interdomain interactions. In mammalian cells, the ∆F508-CFTR
misfolds, resulting in cellular mistrafficking via its accumulation
in the ER (Cheng et al., 1990). As shown by limited proteolysis and
pulse chase analysis, the ∆F508 mutation destabilizes NBD1 and
multidomain folding intermediates, implying a more global desta-
bilization of the entire∆F508-CFTR (Zhang et al., 1998; Meacham
et al., 1999; Du et al., 2005; Cui et al., 2007; Rosser et al., 2008; Du
and Lukacs, 2009). The homology model of CFTR places the F508
position at an interface between NBD1 and ICL4 of TMD2 (Men-
doza and Thomas, 2007). Consistent with this, ∆F508 disrupts
WT-like crosslinks between ICL4 and NBD1 and within the TMDs
(Chen et al., 2004; Serohijos et al., 2008). Additionally, mutations
in ICL4 can suppress the effect of ∆F508, further supporting a
disruption of this interface (Thibodeau et al., 2010). Recently, the
∆F508-mediated NBD1 misfolding and multidomain assembly
were both shown as essential for correction of∆F508-CFTR (Men-
doza et al., 2012; Rabeh et al., 2012). This is consistent with the
known∆F508 effects on NBD1 folding, which is a prerequisite for
its interdomain interactions and formation of an NBD1 surface for
ICL4 interactions. However, these experiments have not yet been
able to identify the timing or mechanism(s) of domain interaction
disruption. The point at which∆F508 effects are detectable and the
ability to target multiple steps to rescue the∆F508 protein empha-
sizes the multistep misfolding of ∆F508-CFTR. Further details
regarding this misfolding are needed to continue to rationally
devise new therapeutic interventions.
Other methods to rescue ∆F508-CFTR continue to be
explored. For instance, compounds have been identified that res-
cue∆F508-CFTR mutation via interactions with the TMDs (Loo
et al., 2011). ∆F508 and other mutant CFTRs were also par-
tially rescued by transcomplementation, in which co-expression
of parts of CFTR were able to improve trafficking of CF-mutant
CFTR from the ER (Cormet-Boyaka et al., 2004; Cebotaru et al.,
2008). Insights into the rescue of ∆F508-CFTR also come from
the yeast homologous ABC exporter, Yor1p (Pagant et al., 2007,
2008). When a∆F508 mimic is introduced into Yor1p, consequent
mistrafficking and degradation occurs (Pagant et al., 2007). Two
Yor1p suppressor mutations in the TM-ICL juncture were found
to correct the ∆F508 mimic (Pagant et al., 2010), suggesting that
modification of the ICL structures rather than direct stabilization
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of the NBD-ICL interface is a potential target for correction of
∆F508-CFTR. Also, a co-expressed Yor1p NBD1 was able to swap
into the ∆F508 mimic-Yor1p to replace the defective domain
(Louie et al., 2010). Notable differences exist between the Yor1p
protein and CFTR; however these findings provide insight into
potential mechanisms for∆F508-CFTR correction that should be
investigated directly with CFTR.
RESCUING MUTANT CFTR
It is suggested that only 10–35% of CFTR function is needed to
positively impact pulmonary disease (Kerem, 2004), therefore the
production and residual activity of mutant CFTR is relevant for
clinical outcomes. In CF, there is a focus on rescuing the defective
CFTR protein. Ongoing therapeutic developments are aimed at
targeting mutations that introduce premature termination codons,
decrease chloride channel function, and alter cellular trafficking,
which are discussed elsewhere within this Research Topic. For
∆F508 and other missense mutations, two aspects to rescuing
mutant CFTR protein are to rescue processing and function, both
of which are innately linked to CFTR structure.
Thus far, great success has occurred in rescuing the CF-causing
G551D mutant. G551D-CFTR has normal cell surface expression
and half-life, but confers a severe defect in channel gating (Welsh
and Smith, 1993). The compound VX-770 was initially charac-
terized as a CFTR potentiator in CF airway epithelial cells (Van
Goor et al., 2009). This compound has since undergone clinical
trials showing efficacy in CF patients (Accurso et al., 2010; Ram-
sey et al., 2011), has been approved by the FDA for treatment of
G551D based CF in patients over 6 years old, and is now mar-
keted as Kalydeco™. These results are promising for CF patients
as adults, who already have lung scarring and dysfunction, and
for children, who may be able to avoid lung dysfunction with this
therapeutic. This success has generated a foundation to guide fur-
ther progress in CF therapeutic development for other mutants,
such as∆F508.
∆F508 and other mutants that cause CFTR misfolding, mis-
trafficking, and disrupted channel function are the largest CF
therapeutic target. The ∆F508-CFTR exhibits a temperature sen-
sitive trafficking from the ER, in which it is retained in the ER
at 37˚C, but partially traffics from the ER at lower temperatures
(Denning et al., 1992). This imparts the idea that trafficking cor-
rection is feasible for ∆F508 if a chemical compound can mimic
the temperature rescue. However, ∆F508-CFTR that is induced
to fold/traffic by low temperature or chemical modifier treat-
ments has disrupted chloride channel function (Dalemans et al.,
1991) and shorter residence times at the cellular surface (Lukacs
et al., 1993), indicating the native structure is not achieved. This
makes approaching∆F508-CFTR a complex problem. Recently, it
was found that correction of both the ∆F508-NBD1 defect and
the ∆F508-NBD1-ICL4 interaction defect are required to rescue
∆F508, consistent with at least two steps for correction of∆F508-
CFTR (Mendoza et al., 2012; Rabeh et al., 2012). ∆F508 is being
targeted pharmacologically by strategies that aim to correct the
trafficking defect and potentiate channel function. Currently tri-
als of VX-809 or VX-661, to correct trafficking, and Kalydeco™, to
potentiate channel function, are ongoing. However, development
of a combination therapy is exponentially more complicated and
difficult. Ideally, a single compound to both correct and potenti-
ate mutant CFTR will be identified (Sheppard, 2011). Extensive
work has gone into describing ∆F508-CFTR misfolding in order
to identify the most pertinent misfolding step(s) for generating
the most relevant therapeutic target.
DISCUSSION
Cystic fibrosis transmembrane conductance regulator structural
development occurs in a complex manner (Figure 3). It requires
formation of TMD1, which involves TM span interactions with
the translocation machinery in the ER. Then production of two
cytosolic domains occurs, first NBD1 and then R. Following this,
yet another TMD must be appropriately integrated, with the pro-
tein structure completed after the production of cytosolic NBD2.
In the final structure, these domains form extensive interdomain
interactions, with the later interaction surfaces having no obvi-
ous interaction partners prior to formation of the final structure.
For instance, during translation, the TM and ICL regions that
form later interdomain interactions are present minutes prior
to production of their interaction partners. These regions are
very hydrophobic and are unlikely to be stable without their
partner sequences or other protein interactions. While the ICL
helical bundle likely forms only when both TMD1 and TMD2
are present, this has not been tested experimentally. It is not
known if ICL structure formation begins in TMD1, or what hap-
pens to the coupling helices before both NBDs are present. A
requirement of this structure for NBD docking onto the ICLs
has not been examined. Knowledge of the timing of this struc-
ture formation and its role in TMD-NBD interactions will be
required for better understanding development of ABC trans-
porter structure. The interactions required for the formation
of native CFTR structure are important for understanding CF-
mutant mediated misfolding, which is a therapeutic target for
correcting CF-mutant CFTR.
Experimental evidence supports that the first four domains
of CFTR undergo a multidomain rearrangement, since a regu-
lated chloride channel that can traffic to the plasma membrane is
formed (Cui et al., 2007). The cell is able to monitor and deter-
mine whether the TMD2 containing construct should traffic from
the ER (Cui et al., 2007; Du and Lukacs, 2009; Thibodeau et al.,
2010). This suggests that, upon the translation of TMD2, the pro-
tein quality control machinery makes a distinction between folded
and unfolded CFTR. A hierarchical folding model also predicts
that two and three domain hierarchical interactions also form
(Figure 3). Though this model is appealing, little evidence exists
to support domain associations prior to the translation of TMD2.
The most suggestive evidence of interdomain interactions in the
first two and three domains of CFTR is the formation of a more
stable three domain construct (Meacham et al., 1999; Rosser et al.,
2008; Grove et al., 2009). In these studies, the interdomain interac-
tions are implied rather than directly tested. Much of the evidence
for formation of multidomain units is forced to rely on the use of
modeling and perturbing mutations to detect the structural units.
It is clear, however, that the most highly studied mutants, specif-
ically ∆F508, alter domain structure in a manner recognizable
by the cell (Du and Lukacs, 2009), convoluting the interpreta-
tion of multidomain complexes with domain effects. A continuing
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effort to analyze native and mutant CFTR and to develop assays to
better study multidomain unit formation are required to continue
addressing these specific issues.
It is important to consider that CFTR cotranslational interac-
tions may be directly related to the order of domain translation.
If these interactions are required sequentially for structure forma-
tion, then a linear peptide should be essential to produce folded
CFTR. However, CFTR expressed as two pieces underwent cellular
trafficking as monitored by glycosylation (Ostedgaard et al., 1997;
Chan et al., 2000; Csanady et al., 2000; Du and Lukacs, 2009),
inconsistent with the model. By contrast, the ability of split CFTR
to form functional protein is consistent with other ABC trans-
porters within which the modular formation of domain structure
indicates that one domain is not required for the formation of
other domains (Locher, 2009). Yet, during in vitro refolding of
the modular ABC transporter, BtuCD, refolding from partially
unfolded units resulted in the highest functional measures (Di
Bartolo et al., 2011). This suggests that domain interactions dur-
ing folding may play a role in increasing the production yield of
functional protein. For CFTR, these interactions could be poten-
tiated by the linear arrangement and be important for generating
enough functional protein to maintain normal physiology. This
may play a role in reaching a level of physiologically functional
CFTR required to alter the progression of CF therapeutically.
Cystic fibrosis clinically impacts multiple organ systems, such
that treatment of the basic defect in CFTR is the best way to address
the widespread morbidities. Novel therapeutics show tremendous
promise for altering the molecular pathologies of CF, however,
implementation of therapeutics designed to correct the most com-
mon mutant,∆F508, is difficult. The∆F508 molecular pathology
is complex and involves multiple levels of misfolding and recog-
nition thereof in the cell. Indeed, ∆F508-CFTR misfolds and is
accumulated in the ER (Cheng et al., 1990). Moreover, if the
trafficking defect is overcome, cell surface ∆F508-CFTR displays
reduced chloride transport (Dalemans et al., 1991) and an accel-
erated turnover rate (Lukacs et al., 1993). Addressing each effect
individually is inadequate, and a successful combination of thera-
peutics has not yet been identified to effectively rescue the∆F508
mutation and remains an untraveled therapeutic path. Suppres-
sor mutations of ∆F508 have been identified within NBD1 (Teem
et al., 1993) and within ICL4 (Thibodeau et al., 2010), which cor-
rect NBD1 folding and/or multidomain folding. But, individually,
these suppressors have limited efficacy. It is now established that
correction of at least two steps are needed to rescue∆F508, includ-
ing NBD1 folding and interdomain interactions (Mendoza et al.,
2012; Rabeh et al., 2012). If the effects of the different suppressor
mutations for ∆F508 either within NBD1 or distant in the CFTR
protein can be mimicked and combined in a small molecule this
could prove an effective therapeutic. It is clear from these studies
that the identification of disease mechanisms that may be targeted
therapeutically requires a global understanding of CFTR struc-
ture. Future disease modifying compounds will be more effective
if the target is the most relevant biological defect.
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